Cytokinetics/$CYTK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cytokinetics
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Ticker
$CYTK
Sector
Primary listing
Employees
673
Headquarters
Website
Cytokinetics Metrics
BasicAdvanced
$7.8B
-
-$6.54
0.51
-
Price and volume
Market cap
$7.8B
Beta
0.51
52-week high
$70.98
52-week low
$29.31
Average daily volume
2M
Financial strength
Current ratio
4.529
Quick ratio
4.358
Long term debt to equity
-206.352
Total debt to equity
-218.13
Interest coverage (TTM)
-5.89%
Profitability
EBITDA (TTM)
-602.133
Gross margin (TTM)
-372.55%
Net profit margin (TTM)
-891.60%
Operating margin (TTM)
-695.44%
Revenue per employee (TTM)
$130,000
Management effectiveness
Return on assets (TTM)
-27.08%
Return on equity (TTM)
197.47%
Valuation
Price to revenue (TTM)
85.877
Price to book
-11.73
Price to tangible book (TTM)
-11.73
Price to free cash flow (TTM)
-14.137
Free cash flow yield (TTM)
-7.07%
Free cash flow per share (TTM)
-4.453
Growth
Revenue change (TTM)
376.56%
Earnings per share change (TTM)
24.14%
3-year revenue growth (CAGR)
-2.36%
10-year revenue growth (CAGR)
11.88%
3-year earnings per share growth (CAGR)
14.71%
10-year earnings per share growth (CAGR)
21.02%
What the Analysts think about Cytokinetics
Analyst ratings (Buy, Hold, Sell) for Cytokinetics stock.
Cytokinetics Financial Performance
Revenues and expenses
Cytokinetics Earnings Performance
Company profitability
Cytokinetics News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cytokinetics stock?
Cytokinetics (CYTK) has a market cap of $7.8B as of March 21, 2026.
What is the P/E ratio for Cytokinetics stock?
The price to earnings (P/E) ratio for Cytokinetics (CYTK) stock is 0 as of March 21, 2026.
Does Cytokinetics stock pay dividends?
No, Cytokinetics (CYTK) stock does not pay dividends to its shareholders as of March 21, 2026.
When is the next Cytokinetics dividend payment date?
Cytokinetics (CYTK) stock does not pay dividends to its shareholders.
What is the beta indicator for Cytokinetics?
Cytokinetics (CYTK) has a beta rating of 0.51. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.